Chris Hempel, Ph.D.
Chris combines deep career expertise in neuroscience and assay development with a passion for gene therapy. Prior to co-founding Expressive Neuroscience, he was at biotech startups Galenea and Q-State Biosciences where he brought online novel, high-throughput assays probing nervous system function. Here he also led discovery collaborations with major disease foundations and pharmaceutical partners. During his previous academic career at UCSD and Brandeis, Chris published in high-profile journals in various neuroscience disciplines. Chris holds a B.Sc. in Biology from the University of Toronto and a Ph.D. in Biology from the University of California, San Diego.
Eric Olson, Ph.D.
Eric Olson, Ph.D.
Eric brings over 25 years of experience in academic neuroscience to Expressive. His academic work examines neurodevelopmental disorders that cause intellectual disability, epilepsy and autism. His involvement with Expressive is driven by the realization that recent advancements in gene therapy puts cures for many of these diseases within reach. Eric performed postdoctoral work at Beth-Israel Deaconess Medical Center in Boston and received his PhD at the University of California San Diego. Dr. Olson is currently an Associate Professor of Neuroscience and Physiology at the State University of New York (SUNY) in Syracuse.
David Rose, Ph.D.
With more than 20 years in the biotechnology industry, Dave brings extensive expertise in database design, process automation, application development and bioinformatics to the development of EXPERT, Expressive’s proprietary data management and analytics platform. Following a Ph.D. in Biology from Harvard University and post-doctoral work at Harvard Medical School, he has worked in drug discovery informatics across a wide range of technologies and disease areas – including 14 years in CNS drug discovery platform development - at companies including Millennium Pharmaceuticals, Galenea Corp., and Q-State Biosciences.